Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report

Olaparib is (ADP‐ribose) polymerase inhibitor (PARPi), which stops the repair of single-stranded DNA breaks. This leads to the death of cancer cells with BRCA1/BRCA2 mutations or homologous recombination deficiency. Since being approved by the FDA in 2023 for treating castrate-resistant prostate can...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Elrazi A Ali, Monika Jain, Akriti Pokhrel, Unni Mooppan, Jen chin Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-01-01
coleção:	Leukemia Research Reports
Assuntos:	Aplastic anemia Olaparib Prostate cancer Pancytopenia
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2213048924000633
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!